Skip to main content

Table 4 Base-case and univariate sensitivity analysis results

From: Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

 

Dapagliflozin

Placebo

Difference

QALYs

10.96

10.88

0.08

Total costs (€)

€ 56,984

€ 59,905

€ -2921

Acquisition of drug

€ 4985

€ 0

€ 4985

T2DM Complicationsa

€ 50,916

€ 58,824

€ -7908

Macrovascular

€ 12,959

€ 13,612

€ -653

Microvascular

€ 37,957

€ 45,212

€ -7255

Hypoglycemic eventsb

€ 19

€ 23

€ -4

Adverse eventsc

€ 1064

€ 1058

€ 6

ICER (€/QALY)

  

Dominant

Sensitivity analysis

∆ Costs

∆ QALY

ICER (€/QALY)

Time horizon: lifetime

€ -3590

0.08

Dominant

Time horizon: 20 years

€ -963

0.06

Dominant

Discount rate: 0%

€ -6361

0.12

Dominant

Discount rate: 5%

€ -1553

0.06

Dominant

Baseline age: 40 years

€ -6086

0.10

Dominant

Baseline age: 70 years

€ -992

0.06

Dominant

Baseline eGFR: 70 ml/min/1.73m2

€ -5120

0.07

Dominant

  1. a Microvascular and macrovascular complications included: unstable angina, myocardial infarction, heart failure, stroke, end-stage kidney disease, blindness, and ulcers
  2. b Only severe hypoglycemic events were included
  3. c The costs of managing urinary and genital tract infections, diabetic acidosis, fractures and acute kidney failure were included
  4. eGFR estimated glomerular filtration rate, ICER incremental cost-effectiveness ratio, QALY Quality-adjusted life year, T2DM Type 2 diabetes mellitus
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us